Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia.
diagnosis
focal
imaging
lytic
myeloma
plasma cell
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
24
06
2021
received:
29
04
2021
accepted:
30
06
2021
entrez:
19
10
2021
pubmed:
20
10
2021
medline:
26
10
2021
Statut:
ppublish
Résumé
Imaging modalities for multiple myeloma (MM) have evolved to enable earlier detection of disease. Furthermore, the diagnosis of MM requiring therapy has recently changed to include disease prior to bone destruction, specifically the detection of focal bone lesions. Focal lesions are early, abnormal areas in the bone marrow, which may signal the development of subsequent lytic lesions that typically occur within the next 18-24 months. Cross-sectional imaging modalities are more sensitive for the detection and monitoring of bone and bone marrow disease and are now included in the International Myeloma Working Group current consensus criteria for initial diagnosis and treatment response assessment. The aim of this consensus practice statement is to review the evidence supporting these modalities. A more detailed Position Statement can be found on the Myeloma Australia website.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1707-1712Informations de copyright
© 2021 Royal Australasian College of Physicians.
Références
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538-48.
Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 2019; 20: e302-e12.
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328-e46.
Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology 2004; 231: 11-23.
Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 2015; 33: 657-64.
Princewill K, Kyere S, Awan O, Mulligan M. Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey. Cancer Invest 2013; 31: 206-11.
Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017; 18: e206-e17.
Chantry A, Kazmi M, Barrington S, Goh V, Mulholland N, Streetly M et al. Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol 2017; 178: 380-93.
Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P et al. Standardization of 18F-FDG-PET/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol 2020; 39: JCO.20.00386.
Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, de Luca S et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study. Clin Nucl Med 2015; 40: 303-8.
Mosci C, Pericole FV, Santos AO, Lima MC, Etchebehere ECC, Amorim BJ et al. A prospective study comparing 99mtc-Sestamibi SPECT/CT with 18f-FDG PET/CT in multiple myeloma staging: a potential resource-constraint image alternative for MM bone evaluation. Blood 2018; 132: 3543.
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A. Non-biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation et al, 2016; 133: 2404-12.
Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen CD et al. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007; 109: 1617-26.
Hanrahan CJ, Christensen CR, Crim JR. Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT. Radiographics 2010; 30: 127-42.
Merz M, Wagner-Gund B, Neben K, Ho AD, Goldschmidt H, Hillengass J. Longitudinal whole body MRI (wbMRI) in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. J Clin Oncol 2013; 31: 8590.
Merz M, Hielscher T, Wagner B, Sauer S, Shah S, Raab MS et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia 2014; 28: 1902-8.
Mangiacavalli S, Cocito F, Pochintesta L, Pascutto C, Ferretti V, Varettoni M et al. Monoclonal gammopathy of undetermined significance: a new proposal of workup. Eur J Haematol 2013; 91: 356-60.
Rajkumar SV, Kyle RA, Therneau TM, Melton LJ III, Bradwell AR, Clark RJ et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812-7.